Wednesday, 18th November COSA 2015 ASM

Speaker: Professor Greg Woods

Content: Since undertaking studies on the Tasmanian devil, major progress has been made in understanding its immune system and how devil facial >tumour disease (DFTD) escapes immune recognition. Involvement with the Devil Facial Tumour Disease has created unique opportunities and research programmes and showed for the first time that devils can produce an immune response to DFTD.

Professor Woods' research interests are primarily aimed at how cancer cells escape detection by the immune system. His major research programme is to evaluate the immune system of the Tasmanian devil and to understand how devil facial tumour disease can be transmitted between devils with the ultimate objective to develop strategies to protect devils from this infectious cancer.

The presentation will focus on the immunology of DFTD, where it originated, how it is transmitted, how the cancer cells avoid activating an immune response when transmitted between devils and the latest in progress towards a vaccine. Find out about this and efforts to re-populate Tasmania's decimated devil population at this seminar to be delivered by the world renowned and award-winning researcher Professor Greg Woods.

Speakers: Assoc Prof Sabe Sabesan

Content: In this session we will be launching the COSA Teleoncology Guidelines, which have been developed by a multidisciplinary COSA writing committee with consultation of COSA members. As teleoncology models are becoming part of the core business of many cancer clinicians to provide care closer to home for rural and remote patients, COSA has embarked on pooling together the evidence and making recommendations for use of teleoncology models. Join us for the launch of this exciting COSA initiative.

Speaker: Dr Richard Sullivan

Content: For any oncologist, treatment of pain remains a priority to ensure optimal function and comfort for the patient. Yet pain in a patient with cancer is complex, as it can evolve with disease progression and can be caused by not only the tumour, but also by the cancer therapy and cancer-related debility. Furthermore, the mechanisms underlying cancer-related pain are often mixed and can involve nociceptive and/or neuropathic pain.

This symposium will explore current understanding of the pathophysiological mechanisms underlying cancer pain and highlight the rationale behind a mechanism-based approach to managing cancer pain. A recent pharmacological treatment for cancer pain will be reviewed in this context.

Content: Therapeutic agents that potentiate the tumour-destructive capabilities of the immune system are revolutionising the treatment of many cancers, including metastatic melanoma and lung cancer. Known as immuno-oncology agents, this class of drugs represent a new era in cancer clinical management and differ considerably from surgery, chemotherapy, radiotherapy and targeted therapy-based treatments.

This symposium will provide attendees with a scientific and clinical overview of the mechanism of action, efficacy and safety of these immuno-oncology agents in patients with metastatic melanoma and lung cancer, including discussion on practical clinical considerations for patients.

• Rare subtypes of breast cancer - Bruce Mann
• ALK and ROS positive lung cancers - Ben Solomon
• BRAF Mutant Colorectal Cancer - Jayesh Desai

• Tumour classification: morphology and molecular, two sides of the same coin - Stephen Fox
• Carcinoma of Unknown Primary - How can a dedicated clinic and molecular profiling help? - Linda Mileshkin
• Genetics of Sarcomas - Angelo Dei Tos
• Molecular classification of ovarian cancer - Clare Scott

• General management of the cancer patient (shared care) – outside the cancer setting The GP’s perspective - Marie Pirotta
• Shared care through Telehealth and e-Health technologies: Pros and Cons - Sabe Sabesan
• Accessing psycho-social support in the community - Alison Hocking
• Models of cancer - Laura Pyszkowski

• Finding the Key to the Lock: Development of the Access Coordinator role in a Cancer Imaging Department - Jacqueline Mathieson
• Incidentalomas - Robin Harle
• Rare tumours – can PET help? - Owen Pointon
• The role of interventional radiology in the palliation of cancer - Andreas Adam

• How empowered do carriers of hereditary cancer gene mutations participating in an annual review program feel about managing their cancer risk? - Lucinda Hossack
• The Genomic Cancer Clinical Trial Initiative – collaboration toward achieving common goals - Paul Jackson
• Neuroendocrine tumor (NET) Oceania patient experience: results from the first global NET patient survey - A collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis - John Leyden
• Rare and uncommon cancers: impact on quality of life, psychological morbidity, and use of CAMs - Ian N Olver
• Management of Bone Cancers in Australian Adolescents and Young Adults (AYAs) - Rosemary Harrup
• Analysis of screening program for Von Hippel-Lindau and SDH mutation carriers. - Mathilda Wilding

• Understanding attitudes towards, and experiences of, family caregiver involvement in cancer consultations: A qualitative study - Phyllis Butow
• Examining actual behaviours occurring in triadic (oncologist-patient-family caregiver) consultations: Analyses of audio-taped oncology consultations - Ilona Juraskova
• Describing the range and complexity of family influence in cancer treatment decision-making: The TRIO framework - Rebekah Laidsaar-Powell
• Developing and evaluating practical strategies for oncology clinicians to manage and enhance family caregiver involvement in cancer consultations - Rebekah Laidsaar-Powell

• Gestational Breast Cancer in Australia and New Zealand: A population study - Elizabeth Sullivan
• To terminate or not to terminate? - Kim Hobbs
• Fertility Preservation – What’s New? - Kelly-Anne Phillips
• The safety of cancer therapies in pregnancy - Sally L Brooks

• Thermal ablation of small renal tumours - Andreas Adam
• There is nothing rare about dying! Supporting patients with rare cancers - Michael Ashby
• Cart wheel - Clare Scott
• A rare cancer patient’s perspective - Kate Vines
• Male Breast Cancer: Diagnosis, Treatment and Support. - John Boyages

• Analysing the Evidence - the statistics of small numbers - Andrew Martin
• Meta and Pooled Analysis as tools when numbers are small - Leeka Kheifets
• What Type of Evidence - Alternative trial designs for rare cancers - Martin Stockler
• Generating the evidence - The Forgotten Cancers Project - Fiona Bruinsma

• Dr Dave moves into Web 2.0: Creating a digital supportive care resource from a comic book for children undergoing radiotherapy for cancer - Megan Chiswell
• Expanding the reach of a cancer clinicians communication curriculum: Case study of a Cancer Council multi-state pilot partnership - Megan Chiswell
• Complex cancer surgery for rare cancers: volume-associated outcomes for patients undergoing Pancreaticoduodenectomy in Queensland - Nathan Dunn
• A randomised controlled trial of a psycho-educational booklet to improve psychosexual adjustment for women undergoing pelvic radiotherapy for gynaecological or anorectal cancer. - Franchelle Lubotzky
• Clinician confidence and education preferences for the treatment of oncology patients and survivors amongst physiotherapists and exercise professionals: a comparison of AYA and adult oncology patients - Sharni L Patchell
• Online oral anti-cancer education for community pharmacists: A pilot study - Erica Wales

• Guideline launch - timely initiation of systemic chemotherapy for the treatment of cancer  - Marliese Alexander
• The change to radiotherapy utilisation in a rural area after the establishment of a local service - Rob Zielinski
• Economic evaluation of psychosocial interventions in cancer: A systematic review - Mbathio Dieng
• A randomised controlled trial to improve enrolment to cancer clinical trials - Cat Parker
• Cancer medicine affordability and financial impacts of cancer in Australia: Impacts on decision-making and perceived financial burden - Christine L Paul
• Optimal Care Pathways: Achievements and future directions - Alexandra Philpott

3:20-4:00pm A and B

• Development of a standardised oral anticancer therapy reference manual in a specialist cancer centre pharmacy department - Amelia Ang
• Peninsula Health Workforce Development - Paula N Balchin
• To utilise a change management process to the implementation of the Antineoplastic Drug Administration Course (ADAC) into four health services within the Southern Melbourne region - Angela Caruso
• Australian cancer consumer advocacy movement: at twenty-one, 1994-2015 - Sally Crossing AM
• The cancer cup challenge – running an international program in safety and quality in oncology  - Anna Janssen
• Are self-administered psychosocial interventions as efficacious as guided interventions in the management of chronic health conditions? - Janelle Levesque
• Communication skills training for oncology health care professionals working with culturally and linguistically diverse patients - Bettina Meiser
• Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient - Sagun Parakh
• Patient Understanding of Research in a Medical Oncology Settting - Natasha Roberts
• Development of Standardised Manufacturing Guidelines for Anticancer Therapies - Gail Rowan
• How should we provide education to our patients? - Belinda Steer
• Does the role of evidence, change nursing practice when handling antineoplastic medications and related waste? - Michelle Weston
• Retrospective Audit of patients with Early Breast Cancer Treated at Princess Alexandra Hospital from 2012-2014 to identify  median time from diagnosis of early breast cancer to surgery, median time from surgery to initiation of chemotherapy and rates of re-excision. - Pawan Bajaj
• Establishment of a multidisciplinary team approach to complex pain management in Rural Victoria - Bertilla Campbell
• A cost-benefit evaluation of prophylactic biosimilar filgrastim for breast cancer patients receiving adjuvant TC chemotherapy. - Lisa Crisp
• A snapshot review of the impact of a Rapid Assessment Clinic on the care pattern of febrile neutropenic patients - Madhawa De SIlva
• Coordinating care for people with colorectal cancer: a population-based survey of patient experiences in NSW - Jane M Young
• Audit of compliance with a limitation of medical treatment instrument entitled ‘Goals of Care Plan’ (GOCP) prior to inpatient death at the Royal Hobart Hospital (RHH). - Christine Edwards
• The challenge of treating Lentigo Maligna (LM); An international multicentre randomised trial comparing radiation therapy to imiquimod for patients diagnosed with complex LM - Gerald Fogarty
• Acceptability and utility of a telephone outcall program for carers of persons diagnosed with cancer - Leila Heckel
• Recruitment of carer/person with cancer dyads into a randomised controlled trial: factors associated with non-participation and reasons for decline - Leila Heckel
• Funding a regional cancer clinical trials centre through community engagement - Nicola Hicks
• A state-wide approach to survivorship care in South Australia - Chantelle Hislop
• Perth Metropolitan Hospital Chemotherapy Day Unit Waiting Times and Patient Satisfaction - Siao Nge Hoon
• An audit of pregnancy screening prior to chemotherapy administration - Linfeng Hu
• Evaluating the effectiveness of the Prostate Cancer Clinical Nurse Co-ordinator (PC-CNC) role in Australia - Ilona Juraskova
• Prostate Cancer Clinical Nurse Coordinator (PC-CNC) Role: Qualitative Exploration of the Coordinator Intervention Impact - Ilona Juraskova
• Discussing and prescribing expensive unfunded anticancer drugs in Australia - Deme J Karikios
• An analysis of under-infusing fluorouracil elastomeric infusion devices - Paul Klages
• Review of an innovative health service approach, the Symptom Urgent Review Clinic (SURC), to improve efficiency and quality of care for breast cancer patients receiving adjuvant chemotherapy - Edmond Kwan
• ‘Nutrition’ related calls to a Cancer Helpline: What are they really about? - Katherine Lane
• Patient Factors that Influence Outpatient Chemotherapy Delivery Scheduling Preferences - Peter K H Lau
• “The incidental support group”: The treatment team playing a central role in the sphere of care - Eleanor Law
• Breast Cancer Management and Outcomes  in Regional Victoria    - Lisi Elizabeth Lim
• M-Health: the impact of smartphone technology to improve quality of life outcomes among people with cancer: a randomised controlled trial - Patricia Livingston
• Clinical trial protocol - Implementing clinical practice guidelines for cancer pain in adults to ensure equitable, cost-effective, evidence-based, person-centred care:A phase III pragmatic stepped wedge cluster randomised controlled trial of guidelines and screening with implementation strategies versus guidelines and screening alone to improve pain in adults with cancer attending outpatients oncology and palliative care centres - Melanie Lovell
• Delegate? Skill Share? Or Uni-professional? A Framework to address to address allied health(AH) workforce shortages. - Juanine Passfield
• How deep are the potholes? Quantifying and describing allied health(AH) road blocks to transitioning to local care. - Juanine Passfield
• The Lung Cancer Demonstration Project: Implementation and evaluation of a lung cancer multidisciplinary team (MDT) communication tool for general practitioners (GPs) - Nicole Rankin
• Member experiences in an Australian Translational Cancer Research Centre, Sydney Catalyst, and their understanding of translational research  - Nicole Rankin
• Clinicians views to inform the next Victorian Government Cancer Plan - Esther Sadek
• Screening for Circulating Tumour Cells allows early detection of cancer  - Wolfgang Marz
• Evaluating a direct access colonoscopy program for suspected colorectal cancer. - Sheryl Sim
• Medicinal cannabis in Victoria: potential law reform and Victorian cancer clinicians’ attitudes and experiences - Rachel Whiffen
• Canrefer: Enhancement of the Online Cancer Services Directory for NSW - Kahren White
• The clincal trial pharmacist’s role in reviewing medication related enquiries for patients enrolled in an oncology clinical trial - Samantha Wieringa
• Mapping lung cancer diagnostic pathways: a qualitative study of interviews with lung cancer patients and their caregivers - Sarah York
• Survivorship care for people with colorectal cancer: a population-based survey of patients' experiences and preferences - Jane M Young
• A qualitative research to understand public perception of personalised cancer medicine (PCM) and its application in treatment of advanced lung cancer - Shams Arifeen
• Real world experience from crizotinib in patients with ALK positive advanced NSCLC, from a compassionate use program run in Australia and New Zealand - Justin Binko
• Multidisciplinary Thyroid Cancer Clinic - Roger Allison
• Thyroid Cancer. Not Always Mr Nice Guy. - Roger Allison
• How accurately do research participants report a diagnosis of cancer? - Juliet Anderson
• Second-line chemotherapy in advanced biliary tract cancer: A retrospective series - Daniel Brungs
• Outcomes and pattern of recurrence in patients with Stage III ALK-rearranged Non-Small Cell Lung Cancer treated with curative intent chemo-radiotherapy. - Laird Cameron
• Symptom burden of Australia and New Zealand (ANZ) patients with Neuroendocrine Tumours (NET)  - David L Chan
• A retrospective study of dual ¹⁸F-fluorodeoxyglucose/⁶⁸Gallium DOTATATE (FDG/⁶⁸Ga-DOTATATE) positron emission tomography (PET) grading and its prognostic value in metastatic pancreatic neuroendocrine tumours (PNET) - David L Chan
• Experience of Australia and New Zealand (ANZ) patients with neuroendocrine tumours (NET) treated at a NET specialist centre: Results of a national survey and the Royal North Shore experience - David L Chan
• Adolescents and Young Adults living with cancer: Patterns of Care and Referral in South Western Sydney Local Health District (SWSLHD) - Amrita Chandra
• Implementation of telemedicine as a method for case conferencing in paediatric radiation oncology - Jennifer Chard
• Anal Cancer - A single centre experience - Emily Chen
• An audit of patients with mature T cell non-Hodgkin’s lymphoma by transplant status in Tasmania - Ciara J Conduit
• Retrospective review of stereotactic radiotherapy for Chordoma and Chondrosarcoma of the skull base and spine - Michael Dally
• Association of CCR5Δ32 Mutation in Breast Cancer Patients of Pakistan. - Faria Fatima
• Clinical profile and treatment outcomes of advanced neuroendocrine tumours in rural and remote patients: a retrospective study from a regional cancer centre in North Queensland, Australia. - Umbreen Hafeez
• Treatment and survival outcomes for neoadjuvant chemotherapy in muscle invasive bladder cancer: a retrospective study from several cancer centres in Australia. - Umbreen Hafeez
• Neuroendocrine Transformation of a Presacral Teratoma in Two Patients with Currarino Syndrome - Aimee R Hayes
• Extraordinary response of an aggressive KIT-negative intra-abdominal fibromatosis to therapy with Imatinib mesylate: a Case-report - Hooi Wen Hong
• Efficacy and safety of lenvatinib for the treatment of patients with ¹³¹I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy - Brett Hughes
• Effect of age and lenvatinib treatment on overall survival for patients with ¹³¹I-refractory differentiated thyroid cancer in SELECT - Brett Hughes
• Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in ¹³¹I-refractory differentiated thyroid cancer (SELECT). - Brett Hughes
• Management and outcomes of metastatic leiomyosarcoma in pregnancy - Huda Ismail
• Paraganglioma in a Pregnant Woman – A Case Report - Huda Ismail
• ALK Translocated Non-Small Cell Lung Cancer: Experience from an Australian metropolitan tertiary referral centre. - Malinda Itchins
• Management of Hypertensive Crisis in Paraganglioma-A Case Report - Cheryl Jackson
• Correlation of Body Mass Index (BMI) with recurrence pattern and survival outcomes in endometrial cancer patients receiving adjuvant radiotherapy with or without chemotherapy: a retrospective study - Yada Kanjanapan
• A Retrospective casenotes audit of clinico-pathologic characteristics of Neuroendocrine Tumours in Northern Territory (NET-NT) - Narayan Karanth
• Neuroendocrine carcinoma of the cervix: An exploratory study of the prevalence of emotional and psychological distress levels and needs for support from the patient experience - Nicole Kinnane
• A single centre audit on the pattern of care of patients with well differentiated neuroendocrine tumours compared to current guidelines - Shu Fen Lee
• The experiences of mothers with multiple myeloma living in rural and regional Australia - Janelle V Levesque
• NET Care in Australia; The patient’s perspective of their Neuroendocrine Tumours (NET) and impact of diagnosis - John Leyden
• Case report of two cases of adenoid cystic carcinoma - Nicholas Linklater
• Testicular cancer at the Top End: Retrospective review of case notes from 2000 -2014 - Andrew Lui
• A survey of the current provision of screening tumours for mismatch repair deficiency in Australia: An Inherited Cancer Connect Partnership (ICCon) initiative - Lyon Mascarenhas
• The psychosocial effects of a whole body MRI screening trial in sarcoma patients with a germline TP53 mutation - Kate A McBride
• Developing a Management Algorithm for a Rare Cancer: Desmoid Tumours - Kortnye M Morris
• Metastatic thyroid cancer: three extraordinary cases highlighting management principles and recent advances - Krithika Murali
• Merkel cell carcinoma: lymphatic mapping for target definition in elective radiation therapy of regional nodes - Diana Naehrig
• Utilization of fluorescence in situ hybridization (FISH) in the diagnosis of rare bone and soft tissue neoplasms: experience at the Royal Prince Alfred Hospital, Sydney, Australia. - Sandra O'Toole
• Does the prevalence of anxiety and depression for diffuse large B-cell lymphoma cancer survivors change over time: a prospective study - Devesh V Oberoi
• Patterns of care and outcomes among sarcomatoid renal cell carcinoma patients in South Western Sydney   - Shamsudheen Padinharakam
• Salivary Duct Carcinoma: Clinicopathologic Features, Morphologic Spectrum and Somatic Mutations - Sandra A O’Toole
• Radiotherapy or Chemo Radiotherapy in the treatment of Merkel cell carcinoma. An Update from the Chris O'Brien Lifehouse - Nazmeen Shameem
• Evaluating the utility of the QUAL-EC in the clinical care of patients with advanced cancer - Anne M. Wilkinson
• Experiences of Uncertainty and Invisibility: Women's Accounts of Living with a Rare Cancer - David Wyld

• The mortality trends of Penile Cancer: An Australian Series - Emily Chen
• Cancer survivorship registries for the collection of patient-reported outcomes: a systematic narrative review - Chris Hygonnet
• Clinical response, progression-free survival (PFS) and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) versus IPI monotherapy in CheckMate 069 study - F Stephen Hodi
• Lung cancer prevalence in New South Wales (Australia): Analysis of past trends and projection of future estimates - Xue Qin Yu
• Innovating multidisciplinary triage of head and neck cancer patients and their carers during (chemo)radiotherapy: the "ScreenIT" system - Sandro Porceddu

•  Fear of cancer recurrence post allogeneic hematopoietic stem cell transplant for malignant disease: Adapting to the ‘new normal’.  - Lisa Brice
• Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)? Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥3 lines of chemotherapy (PPS) – The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS). - Peey-Sei Kok
• Which clinical practice guideline for cancer-related fatigue is the most suitable for application in Australia? - Elizabeth JM Pearson
• Supportive care needs of a sample of cancer patients in metropolitan Melbourne: implications for service improvement - Katherine Simons
• Exercise improves quality of life, but not metabolic risk factors in men with prostate cancer undergoing androgen deprivation therapy –results of a meta-analysis. - Laisa Teleni

This sessions follows a highly successful format used at previous meetings. It is designed to provide a forum for discussion of the complex issues which arise in the care of patients with rare cancers. The facilitator will present a series of challenging clinical cases and engage members of the multidisciplinary panel in discussion. There will also be opportunities for members of the audience to contribute to the discussion.

Panel includes:

Michael Ashby – Palliative care physician

Heather Cunliffe – Medical oncologist

Gerald Fogarty – Radiation oncologist

Andrew Hunn – Surgeon

Jenny Langley – Community liaison officer

Richard Vines – Consumer advocate

Melissa Waugh – Occupational therapist

Including Tom Reeve Oration – Professor David Currow